Bioethics of intervention and the case of drugs Bevacizumab and Ranibizumab for retinal diseases
DOI:
https://doi.org/10.14422/rib.i02.y2016.004Keywords:
Bioethics, clinical ethics, biological medicines.Abstract
From the year 2000, on a class of biological drugs, the anti-VEGF proved to be quite effective in the treatment of retinal diseases, which have in its pathophysiological mechanism an important vascular proliferation component that can lead to blindness. Two of these drugs, bevacizumab and ranibizumab, are quite similar and have the same efficacy and safety. They were developed by the same laboratory and are commercialized by two major pharmaceutical companies through an agreement made between them. However, there is a big difference in the price of the drugs. The aim of this article is to present the Bioethics of intervention as grounds for choosing the cheaper drug, even if forced to do so by regulatory entities.
Downloads
References
Avastin (bevacizumabe). Produtos Roche Químicos e Farmacêuticos S.A. Bula Anvisa.
Chakravarthy, U., Harding, S.P., Rogers, C.A., Downes, S.M., Lotery, A.J., Wordsworth S., et al. (2012). Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology, 119 (7) 1399–1411.
Daniels, N. (2008). Just Health. Meeting Health Needs Fairly. Cambridge: Cambridge University Press.
Garrafa, V. (2005). Da bioética de princípios a uma bioética interventiva. Rev.Bioética, 13 (1) 130.
Garrafa, V., Porto, D. (2004). Bioética poder e injustiça: por uma ética de intervenção. In: Garrafa, V., Pessini, L. Bioética: poder e Injustiça. São Paulo: Loyola, 35–44.
Garrafa, V., Porto, D. (2003) Intervention Bioethics: A proposal for peripheral countries in a context of power and injustice. Bioethics, 17 (5-6) 399-416.
Nigel, H. (2012). Avastin is as effective as Lucentis for wet AMD and could save NHS £84m a year, study shows BMJ, 344.
Lucentis (ranibizumabe). Novartis Biociências S.A. Bula Anvisa.
Martin, D.F., Maguire, M.G., Fine, S.L., Ying, G., Jaffe, G.J., Grunwald, J.E, et al. (2012). Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results (CATT Trial). Ophthalmology 119 (7) 1388–1398.
Paranhos, F. R. L. (2015). Crítica à teoria da moralidade comum como fundamentação do principialismo. Tese apresentada Universidade de Brasília para obtenção do título de Doutor em Bioética.
Ross, E. L., Hutton, D. W., Stein, J. D., Bressler, N. M., Jampol, L. M., Glassman, A. R. (2016). Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol. [Epub ahead of print].
Wasserman, E. Roche and Novartis unable to kill €180M fine in Avastin vs. Lucentis case (2014). Fierce Pharma (disponível em http://www.fiercepharma.com/regulatory/roche-and-novartis-unable-to-kill-%E2%82%AC180m-fine-avastin-vs-lucentis-case) (Acessado em 04-06-2016)
Published
How to Cite
Issue
Section
License
The authors of articles published in Revista Iberoamericana de Bioética retain the intellectual property rights over their works and grant the journal their distribution and public communication rights, consenting to their publication under a Creative Commons Attribution-NonCommercial-NoDerivates 4.0 Internacional. Authors are encouraged to publish their work on the Internet (for example, on institutional or personal pages, repositories, etc.) respecting the conditions of this license and quoting appropriately the original source.
